RVTY Revvity, Inc. Common Stock
NYSE · Life Sciences Tools & Services · SEC EDGAR에서 보기 ↗ 종가 10월 2, 2026 10-K/10-Q 8월 11, 2026RVTY 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
RVTY 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
막대 세분성은 선택한 기간에 따라 조정됩니다. 막대의 시가/고가/저가/종가를 보려면 차트에 마우스를 올리세요.
| 배당락일 | 분할 | 유형 |
|---|---|---|
| 2001년 6월 4일 | 2-for-1 | 정방향 |
| 1992년 5월 11일 | 2-for-1 | 정방향 |
| 1982년 2월 2일 | 2-for-1 | 정방향 |
| 1980년 2월 4일 | 2-for-1 | 정방향 |
Revvity, Inc. Common Stock 정보 위키백과 회사 개요
PerkinElmer, Inc., previously styled Perkin-Elmer, is an American global corporation that was founded in 1937 and originally focused on precision optics. Over the years it went into and out of several different businesses via acquisitions and divestitures; these included defense products, semiconductors, computer systems, and others. By the 21st century, PerkinElmer was focused in the business areas of diagnostics, life science research, food, environmental and industrial testing. Its capabilities include detection, imaging, informatics, and service. It produced analytical instruments, genetic testing and diagnostic tools, medical imaging components, software, instruments, and consumables for multiple end markets. PerkinElmer was part of the S&P 500 Index and operated in 190 countries.
Over its history, PerkinElmer has been split in two twice. In 1999, PerkinElmer merged with EG&G, with the ongoing Analytical Instruments Division of Perkin-Elmer keeping that name, while the life sciences division of the company became the separate PE Corporation. In 2022, a split of PerkinElmer resulted in one part, comprising applied, food and enterprise services businesses, being sold to the private equity firm New Mountain Capital for $2.45 billion and thus no longer being public but kept the PerkinElmer name. The other part, comprising life sciences and diagnostics businesses, remained public but required a new name, which in 2023 was announced as Revvity, Inc.
History
Founding
Richard Perkin was attending the Pratt Institute in Brooklyn to study chemical engineering, but left after a year to try his hand on Wall Street. Still interested in the sciences, he gave public lectures on various topics. Charles Elmer ran a firm that supplied court reporters and was nearing retirement when he attended one of Perkin's lectures on astronomy being held at the Brooklyn Institute of Arts and Sciences.
The two struck up a friendship over their shared interest in astronomy, and eventually came up with the idea of starting a firm to produce precision optics. Perkin raised US$15,000 from his relatives, while Elmer added US$5,000, and the firm was initially set up as a partnership on 19 April 1937. Initially, they worked from a small office in Manhattan, but soon opened a production facility in Jersey City. They incorporated the growing firm on 13 December 1939. A further move to Glenbrook in Connecticut in 1941 was quickly followed by another move to Norwalk, Connecticut, where the company remained until 2000. The opening of World War II led to significant expansion as the company produced optics for range finders, bombsights, and reconnaissance systems. This work led to the U.S. Navy awarding them the first "E" for Excellence award in 1942.
Perkin-Elmer retained a strong presence in the military field through the 1960s and at the same time was significantly involved with OAO-3 a 36-inch Ultra Violet Space Telescope and Skylab. They contributed to the Apollo program by development of a CO2 sensor that was, however, supplanted by a Coleman Instruments product. PE at the Norwalk plant also conducted one of the first researches into computer-digital enhancement of scanned images, contracted for application to the Corona spy satellite, film imagery. They were a primary supplier of the optical systems used in many reconnaissance platforms, first in aircraft and high-altitude balloons, and then in reconnaissance satellites. A significant advance was 1955's Transverse Panoramic Camera, which took images on 12 by 14 ft (3.7 by 4.3 m) wide frames that provided single-frame images from horizon to horizon from an aircraft flying at 40,000 ft altitude. Such systems remained a major part of the company's income, capped by the installation of laser retroreflectors on the Moon as part of the Apollo 11 mission.
Elmer died at age 83 in 1954, and the company began trading shares over the counter. The company was listed on the New York Stock Exchange on 13 December 1960. Perkin remained as president and CEO until June 1961, when Robert Lewis, previously of Argus Camera and Sylvania Electric Products, took over these roles. Perkin remained the chairman of the board until his death in 1969.
Semiconductor manufacturing
In 1967, the U.S. Air Force asked Perkin-Elmer to produce an all-optical "masking" system for semiconductor fabrication. Previous systems used a pattern, the "mask", which was pressed onto the surface of the silicon wafer as part of the photolithography process. Small bits of dirt or photoresist would stick the mask and ruin the patterning for subsequent chips, and it was not uncommon for the vast majority of the chips from a given wafer to malfunction. The Air Force, which by the late 1960s was highly reliant on integrated circuits, desired a more reliable system.
Perkin-Elmer responded with the Microprojector, which was essentially a large photocopier system. The mask was placed in a holder and never touched the surface of the chip. Instead, the image was projected onto the surface. Making this work required a complex 16-element lens system that focussed a narrow range of wavelengths of light onto the mask. The remainder of the light from the 1,000 watt mercury-vapor lamp was filtered out. PE also developed a micro-densitometer in 1967 that scanned micro-chips for quality control
Harold Hemstreet was convinced that the concept could be simplified, and Abe Offner began the development of a system using mirrors instead of lenses, which did not suffer from the multispectral focussing problems of lenses. The result of this research was the Projection Scanning Aligner, or Micralign, which made chip making an assembly-line task and improved the number of working chips from perhaps 10% to 70% overnight. Chip prices plummeted as a result, with examples like the MOS 6502 selling for about US$20 while the previous generation of designs like the Motorola 6800 sold for around US$250.
The Micralign was so successful that Perkin-Elmer became the largest single vendor in the chip space in three years. In spite of this success, the company was largely a has-been by the 1980s due to their late response to the introduction of the stepping aligner, which allowed a single small mask to be stepped across the wafer, rather than requiring a single large mask covering the entire wafer. The company never regained their lead, and sold the division to The Silicon Valley Group.
Lab equipment
Perkin Elmer was a leading developer and supplier of lab analytic equipment from the 1950's. By the 1960's the Norwalk/Wilton, CT facilities were developing and producing a wide variety of instruments including multi-spectral spectrometers (IR, visible, UV), gas chromatographs, and atomic absorption spectrometers and Raman spectrometers. The plants housed integrated research, engineering, production (optical and electronic) and support facilities. In the early 1990s, partnered with Cetus Corporation (and later Hoffmann-La Roche) to pioneer the polymerase chain reaction (PCR) equipment industry. Analytical-instruments business was also operated from 1954 to 2001 in Germany, by the Bodenseewerk Perkin-Elmer GmbH located in Überlingen at Lake Constance, and England (Perkin Elmer Ltd) at Beaconsfield in Buckinghamshire.
Computer Systems Division
Perkin-Elmer was involved in computer manufacture for a time. The Perkin-Elmer Computer Systems Division was formed through the purchase of Interdata, Inc., an independent computer manufacturer, in 1973–1974 for some US$63 million. This merger made Perkin-Elmer's annual sales rise to over US$200 million. This was also known as Perkin-Elmer's Data Systems Group. The 32-bit computers were very similar to an IBM System/370, but ran the OS/32MT operating system. In 1976, Perkin-Elmer acquired Wangco, a Los Angeles manufacturer of tape drives for $30 million in a stock swap.
The Computer Systems Division had a large presence in Monmouth County, New Jersey, with some 1,700 staff making it one of the county's largest private employers. Its plant in Oceanport had 800 employees alone. By the early-mid-1980s the computing group had sales of $259 million; while profitable, it tended to have reduced visibility within the computing industry due to being owned by a diversified parent.
The Wollongong Group provided the commercial version of the Unix port to the Interdata 7/32 hardware, known as Edition 7 Unix. The port was originally done by the University of Wollongong in New South Wales, Australia, and was the first UNIX port to hardware other than the Digital Equipment Corporation PDP family. By 1982, the Wollongong Group Edition 7 Unix and Programmer's Workbench (PWB) were available on models such as the Perkin-Elmer 3210 and 3240 minicomputers.
In 1985, the computing division of Perkin-Elmer was spun off as Concurrent Computer Corporation, with the goal of giving it and the parallel processing product a clearer identification within the computer industry. At first, the new company was a wholly owned subsidiary of Perkin-Elmer, but with the intentions of putting a minority ownership in the company up for a public stock sale. This was done one in February 1986, with Perkin-Elmer retaining an 82 percent stake in Concurrent. In 1988, there was a merger between Concurrent Computer Corporation and MASSCOMP; as part of the deal, Perkin-Elmer's share in Concurrent was bought out. At that point, Perkin-Elmer said they had culminated their multi-year process of exiting from computer market, allowing them to focus on their primary business segments.
1999
Modern PerkinElmer traces its history back to a merger between divisions of what had been two S&P 500 companies, EG&G Inc. (formerly NYSE: EGG) of Wellesley, Massachusetts and Perkin-Elmer (formerly NYSE: PKN) of Norwalk, Connecticut. On May 28, 1999, the non-government side of EG&G Inc. purchased the Analytical Instruments Division of Perkin-Elmer, its traditional business segment, for US$425 million, also assuming the Perkin-Elmer name and forming the new PerkinElmer company, with new officers and a new board of directors. At the time, EG&G made products for diverse industries including automotive, medical, aerospace and photography.
The old Perkin-Elmer Board of Directors and Officers remained at that reorganized company under its new name, PE Corporation. It had been the Life Sciences division of Perkin-Elmer, and its two component tracking stock business groups, Celera Genomics (NYSE: CRA) and PE Biosystems (formerly NYSE: PEB), were centrally involved in the highest profile biotechnology events of the decade, the intense race against the Human Genome Project consortium, which then resulted in the genomics segment of the technology bubble. Perkin-Elmer purchased the Boston operations of NEN Life Sciences in 2001.
Recently
In 1992, the company merged with Applied Biosystems. In 1997 they merged with PerSeptive Biosystems. On July 14, 1999, the new analytical instruments maker PerkinElmer cut 350 jobs, or 12%, in its cost reduction reorganization. In 2006, PerkinElmer sold off the Fluid Sciences division for approximately US$400 million; the aim of the selloff was to increase the strategic focus on its higher-growth health sciences and photonic markets. Following on from the selloff, a number of small businesses were acquired, including Spectral Genomics, Improvision, Evotec-Technologies, Euroscreen, ViaCell, and Avalon Instruments. The brand "Evotec-Technologies" remains the property of Evotec, the former owner company. PerkinElmer had a license to use the brand until the end of year 2007.
PerkinElmer has continued to expand its interest in medicine with the acquisitions of clinical laboratories, In July 2006, it acquired NTD Labs located on Long Island, New York. The laboratory specializes in prenatal screening during the first trimester of pregnancy. In 2007, it purchased ViaCell, Inc. for US$300 million, which included its offices in Boston and cord blood storage facility in Kentucky near Cincinnati. The company was renamed ViaCord.
In 2001 Perkin Elmer acquired Packard Bioscience Inc from its majority shareholder, Dick McKernen. This acquisition also came with Agincourt Technologies Inc and consolidated Perkin Elmer's position in laboratory robotics, in particular, liquid handling robots which were to prove essential for the high-throughput sequencing needed for the Human Genome Project.
In March 2008, PerkinElmer purchased Pediatrix Screening (formerly Neo Gen Screening), a laboratory located in Bridgeville, Pennsylvania specializing in screening newborns for various inborn errors of metabolism such as phenylketonuria, hypothyroidism, and sickle-cell disease. It renamed the laboratory PerkinElmer Genetics, Inc.
In May 2011, PerkinElmer announced the signature of an agreement to acquire CambridgeSoft, and the successful acquisition of ArtusLabs.
In September 2011, PerkinElmer bought Caliper Life Sciences for US$600 million.
In December 2014 PerkinElmer acquired Perten Instruments for US$266 million to expand in food testing.
In January 2016, PerkinElmer acquired Swedish firm Vanadis Diagnostics.
In February 2016 PerkinElmer acquired Delta Instruments.
In January 2017, the company announced it would acquire the Indian in vitro diagnostic company, Tulip Diagnostics. In May 2017, the company acquired Euroimmun Medical Laboratory Diagnostics for approximately US$1.3 billion.
In 2018, the company acquired Australian biotech company, RHS Ltd., Chinese manufacturer of analytical instruments, Shanghai Spectrum Instruments Co. Ltd., and France-based company Cisbio Bioassays, which specializes in diagnostics and drug discovery solutions.
In November 2020, PerkinElmer announced it would acquire Horizon Discovery Group for around US$383 million.
In March 2021, PerkinElmer announced that the company has completed its acquisition of Oxford Immunotec Global PLC (Oxford Immunotec). In May of the same year, the business announced it would purchase Nexcelom Bioscience for $260 million and Immunodiagnostic Systems Holdings PLC for $155 million. In June the company announced it would acquire SIRION Biotech, a specialist in viral vector gene delivery methods. In July the business announced it would acquire BioLegend for $5.25 billion.
Acquisition history
Programs
Hubble optics project
Perkin-Elmer's Danbury Optical System unit was commissioned to build the optical components of the Hubble Space Telescope. The construction of the main mirror began in 1979 and completed in 1981. The polishing process ran over budget and behind schedule, producing significant friction with NASA. Due to a miscalibrated null corrector, the primary mirror was also found to have a significant spherical aberration after reaching orbit on STS-31. Perkin-Elmer's own calculations and measurements revealed the primary mirror's surface discrepancies, but the company chose to withhold that data from NASA. A NASA investigation heavily criticized Perkin-Elmer for management failings, disregarding written quality guidelines, and ignoring test data that revealed the miscalibration. Corrective optics were installed on the telescope during the first Hubble service and repair mission STS-61. The correction, Corrective Optics Space Telescope Axial Replacement, was applied entirely to the secondary mirror and replaced existing instrumentation; the aberration of the primary mirror remained uncorrected.
The company agreed to pay US$15 million, essentially forgoing its fees in polishing the mirror, to avoid a threatened liability lawsuit under the False Claims Act by the Federal government. Hughes Aircraft, which acquired the Danbury Optical System unit one month after the launch of the telescope, paid US$10 million. The Justice Department asserted that the companies should have known about the flawed testing. Trade group Aerospace Industries Association protested when concerns were raised in the aerospace industry that aerospace companies might be held liable for failed equipment.
KH-9 Hexagon
Perkin-Elmer built the optical systems for the KH-9 Hexagon series of spy satellites at a facility in Danbury, Connecticut.
출처: 위키백과 (영어), CC BY-SA 4.0 · 위키백과에서 보기 ↗
10년 성과 매출, 순이익, 마진 및 EPS 추세
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
| 지표 | 5년 추세 | RVTY | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| P/E | 46.75년 평균 ≈34.7 | ≈34.7 | 46.0 | 고평가 | |
| P/S | 3.85년 평균 ≈5.1 | ≈5.1 | 7.1 | 저평가 | |
| P/B (MRQ) | 2.35년 평균 ≈2.2 | ≈2.2 | 6.8 | 저평가 | |
| EV / EBITDA | 17.35년 평균 ≈19.0 | ≈19.0 | 25.4 | 저평가 | |
| Price / FCF (주가 / FCF) | 21.35년 평균 ≈291.5 | ≈291.5 | · | · | |
| Price / Cash Flow (주가 / 현금 흐름) | 18.65년 평균 ≈46.4 | ≈46.4 | 28.0 | 저평가 | |
| EV / Revenue (EV / 매출) | 4.65년 평균 ≈6.1 | ≈6.1 | · | · | |
| EV / FCF | 25.85년 평균 ≈341.5 | ≈341.5 | · | · | |
| 주가 / 유형 장부 가치 (MRQ) | 3.4 | · | · | · |
동종 기업 중앙값은 지표별로 표준화된 기준으로 계산되며, 이 주식에 표시된 TTM/MRQ 기준과 항상 일치하지 않을 수 있습니다.
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
| 지표 | 5년 추세 | RVTY | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| Operating Margin (영업이익률) | 12.5%5년 평균 ≈16.9% | ≈16.9% | 17.4% | 약함 | |
| EBITDA Margin (EBITDA 마진) | 26.7%5년 평균 ≈30.0% | ≈30.0% | 18.6% | 약함 | |
| Pretax Margin (세전 마진) | 9.4%5년 평균 ≈14.5% | ≈14.5% | 17.9% | 약함 | |
| Net Profit Margin (순이익률) | 8.5%5년 평균 ≈15.9% | ≈15.9% | 14.7% | 약함 | |
| ROA | 2.0%5년 평균 ≈4.2% | ≈4.2% | 9.8% | 약함 | |
| ROE | 3.3%5년 평균 ≈7.4% | ≈7.4% | 11.0% | 약함 | |
| ROIC | 3.0%5년 평균 ≈4.3% | ≈4.3% | 13.4% | 약함 |
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
| 지표 | 5년 추세 | RVTY | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| 부채 / 자기자본 비율 (MRQ) | 0.45년 평균 ≈0.5 | ≈0.5 | 0.2 | 높은 부채 | |
| 유동비율 (MRQ) | 1.85년 평균 ≈2.3 | ≈2.3 | 1.8 | 동일 | |
| Quick Ratio (당좌 비율) | 1.35년 평균 ≈1.5 | ≈1.5 | 1.0 | 강한 유동성 | |
| 장기 부채 / 자기 자본 (MRQ) | 0.45년 평균 ≈0.5 | ≈0.5 | 0.4 | 동일 |
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
| 지표 | 5년 추세 | RVTY | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| Revenue YoY (매출 YoY) | 3.7%5년 평균 ≈-5.1% | ≈-5.1% | · | · | |
| Revenue CAGR 3Y (매출 CAGR 3년) | -4.8%5년 평균 ≈-8.4% | ≈-8.4% | · | · | |
| Revenue CAGR 5Y (매출 CAGR 5년) | -5.5% | · | · | · | |
| EPS YoY | -5.9%5년 평균 ≈-12.6% | ≈-12.6% | · | · | |
| Net Income YoY (순이익 YoY) | -10.8%5년 평균 ≈-12.0% | ≈-12.0% | · | · | |
| EPS CAGR 3Y (EPS CAGR 3년) | -22.8%5년 평균 ≈-21.0% | ≈-21.0% | · | · | |
| EPS CAGR 5Y (EPS CAGR 5년) | -20.4% | · | · | · | |
| Net Income CAGR 3Y (순이익 CAGR 3년) | -24.9%5년 평균 ≈-20.2% | ≈-20.2% | · | · | |
| Net Income CAGR 5Y (순이익 CAGR 5년) | -19.8% | · | · | · |
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
| 지표 | 5년 추세 | RVTY | 5년 평균 | 동종업계 중앙값 | 결론 |
|---|---|---|---|---|---|
| Asset Turnover (자산 회전율) | 0.25년 평균 ≈0.3 | ≈0.3 | 0.6 | 약함 | |
| Receivables Turnover (매출 채권 회전율) | 4.15년 평균 ≈4.5 | ≈4.5 | 5.5 | 약함 | |
| Revenue / Employee (연간 매출액 ÷ 직원 수(yfinance 보고 인원수). 파생 — 저장된 SEC-XBRL 개념이 아님.) | ≈$259.6K | · | · | · |
가치 · ≈ 5년 평균 · 산업 중앙값 · 중앙값 대비 평가
배당금 배당 수익률, 지급 비율, 배당 이력, 5년 CAGR
| 배당락일 | 금액 | 통화 | 수익률 |
|---|---|---|---|
| 7월 17, 2026 | $0.07 | USD | ≈0.25% |
| 4월 17, 2026 | $0.07 | USD | ≈0.30% |
| 1월 16, 2026 | $0.07 | USD | ≈0.25% |
| 10월 17, 2025 | $0.07 | USD | ≈0.30% |
| 7월 18, 2025 | $0.07 | USD | ≈0.30% |
| 4월 17, 2025 | $0.07 | USD | ≈0.30% |
| 1월 17, 2025 | $0.07 | USD | ≈0.24% |
| 10월 18, 2024 | $0.07 | USD | ≈0.23% |
| 7월 19, 2024 | $0.07 | USD | ≈0.26% |
| 4월 18, 2024 | $0.07 | USD | ≈0.28% |
| 1월 18, 2024 | $0.07 | USD | ≈0.26% |
| 10월 19, 2023 | $0.07 | USD | ≈0.28% |
| 7월 20, 2023 | $0.07 | USD | ≈0.22% |
| 4월 20, 2023 | $0.07 | USD | ≈0.21% |
| 1월 19, 2023 | $0.07 | USD | ≈0.21% |
| 10월 20, 2022 | $0.07 | USD | ≈0.22% |
| 7월 21, 2022 | $0.07 | USD | ≈0.19% |
| 4월 21, 2022 | $0.07 | USD | ≈0.18% |
| 1월 20, 2022 | $0.07 | USD | ≈0.16% |
| 10월 21, 2021 | $0.07 | USD | ≈0.16% |
실적 기록 EPS 실제 vs 예상, 서프라이즈 %, 달성률, 다음 실적 발표일
| 기간 | 보고서 | EPS Actual | EPS 예상 | 서프라이즈 |
|---|---|---|---|---|
| 2026년 6월 30일 | 7월 27, 2026 | $1.41 | $1.25 | 13.1% |
| 2026년 3월 31일 | $1.06 | $1.04 | 2.3% | |
| 2025년 12월 31일 | $1.70 | $1.58 | 7.4% | |
| 2025년 9월 30일 | $1.18 | $1.16 | 1.7% | |
| 2025년 6월 30일 | $1.18 | $1.16 | 1.5% | |
| 2025년 3월 31일 | $1.01 | $0.97 | 4.3% |
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.86B | $2.76B | $2.75B | $3.31B | $3.83B | $3.78B | $2.88B | $2.78B | $2.26B | $2.12B | $2.10B | $2.24B | |
| Cost of Revenue | · | · | · | · | · | · | · | $1.44B | $709M | $665M | $696M | $708M | |
| Gross Profit | · | · | · | $1.99B | $2.43B | $2.11B | $1.40B | $1.34B | $1.07B | $1.01B | $964M | $1.00B | |
| R&D Expense | $216M | $197M | $217M | $222M | $200M | $146M | $189M | $194M | $139M | $124M | $113M | $108M | |
| SG&A Expense | $992M | $994M | $1.02B | $1.03B | $975M | $716M | $815M | $812M | $626M | $590M | $587M | $648M | |
| Operating Income | $357M | $347M | $301M | $743M | $1.26B | $867M | $362M | $324M | $296M | $295M | $251M | $165M | |
| Interest Expense | · | · | · | · | · | $50M | $64M | $67M | $44M | $42M | $38M | $36M | |
| Interest Income | $31M | $73M | $72M | $4M | $2M | $1M | $1M | $1M | $3M | $702.0K | $673.0K | $667.0K | |
| Other Non-op | $-88M | $-31M | $-118M | $-91M | $-3M | $-5M | $-6M | $-13M | $43M | $-15M | $-5M | $-6M | |
| Pretax Income | $268M | $316M | $183M | $652M | $1.20B | $800M | $237M | $258M | $297M | $244M | $209M | $124M | |
| Income Tax | $28M | $33M | $3M | $139M | $314M | $170M | $9M | $20M | $140M | $28M | $20M | $-6M | |
| Net Income | $241M | $270M | $693M | $569M | $943M | $728M | $228M | $238M | $293M | $234M | $212M | $158M | |
| EPS (Basic) | $2.07 | $2.21 | $5.56 | $4.51 | $8.12 | $6.52 | $2.06 | $2.15 | $2.67 | $2.14 | $1.89 | $1.40 | |
| EPS (Diluted) | $2.07 | $2.20 | $5.55 | $4.50 | $8.08 | $6.49 | $2.04 | $2.13 | $2.64 | $2.12 | $1.87 | $1.39 | |
| Shares (Basic) | 116,542,000 | 122,756,000 | 124,704,000 | 126,155,000 | 116,165,000 | 111,514,000 | 110,827,000 | 110,561,000 | 109,857,000 | 109,478,000 | 112,507,000 | 112,593,000 | |
| Shares (Diluted) | 116,595,000 | 122,822,000 | 124,812,000 | 126,426,000 | 116,674,000 | 112,085,000 | 111,501,000 | 111,534,000 | 110,859,000 | 110,313,000 | 113,315,000 | 113,739,000 | |
| EBITDA | $762M | $775M | $732M | $1.17B | $1.69B | $1.23B | $576M | $504M | $410M | $383M | $398M | $327M |
대차대조표
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $920M | $1.16B | $913M | $454M | $603M | $387M | $192M | $163M | $202M | $359M | $238M | $175M | |
| Short-term Investments | · | $0 | $690M | $0 | · | · | · | · | · | · | · | · | |
| Receivables | $745M | $632M | $633M | $613M | $708M | $1.16B | $725M | $633M | $552M | $426M | $415M | $471M | |
| Inventory | $379M | $368M | $428M | $405M | $426M | $515M | $357M | $338M | $352M | $247M | $259M | $285M | |
| Other Current Assets | $196M | $186M | $337M | $122M | $148M | $167M | $100M | $101M | $94M | $99M | $64M | $138M | |
| Current Assets | $2.24B | $2.35B | $3.00B | $3.29B | $2.44B | $2.24B | $1.37B | $1.23B | $1.20B | $1.19B | $1.03B | $1.07B | |
| PP&E (Net) | $479M | $482M | $510M | $483M | $486M | $368M | $318M | $319M | $298M | $145M | $138M | $176M | |
| PP&E (Gross) | $1.09B | $982M | $983M | $857M | $844M | $818M | $702M | $680M | $631M | $428M | $402M | $493M | |
| Accum. Depreciation | $614M | $500M | $473M | $374M | $359M | $450M | $383M | $362M | $333M | $282M | $264M | $317M | |
| Goodwill | $6.61B | $6.46B | $6.53B | $6.48B | $6.63B | $2.64B | $3.11B | $2.95B | $3.00B | $2.25B | $2.24B | $2.24B | |
| Intangibles | $2.35B | $2.64B | $3.02B | $3.38B | $3.82B | $1.37B | $1.28B | $1.20B | $1.35B | $420M | $486M | $490M | |
| Other Non-current Assets | $323M | $288M | $343M | $311M | $317M | $333M | $284M | $270M | $244M | $205M | $198M | $107M | |
| Total Assets | $12.17B | $12.39B | $13.56B | $14.13B | $15.00B | $7.96B | $6.54B | $5.98B | $6.09B | $4.28B | $4.17B | $4.13B | |
| Accounts Payable | $185M | $167M | $204M | $273M | $325M | $327M | $236M | $221M | $222M | $168M | $141M | $174M | |
| Accrued Liabilities | $557M | $485M | $524M | $528M | $679M | $944M | $503M | $529M | $501M | $400M | $382M | $403M | |
| Current Liabilities | $1.33B | $653M | $1.45B | $1.54B | $1.21B | $1.65B | $763M | $772M | $951M | $603M | $561M | $597M | |
| Capital Leases | $148M | $152M | $133M | $170M | $147M | $188M | $146M | $0 | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | · | $30M | |
| Other Non-current Liabilities | $807M | $771M | $931M | $1.11B | $1.43B | $775M | $751M | $742M | $849M | $460M | $465M | $443M | |
| Total Liabilities | $4.92B | $4.73B | $5.69B | $6.75B | $7.86B | $4.22B | $3.72B | $3.39B | $3.59B | $2.12B | $2.06B | $2.09B | |
| Long-term Debt | $3.22B | $3.15B | $3.90B | $4.39B | $4.98B | $1.99B | $2.07B | $1.89B | $2.01B | $1.05B | $480M | $1.05B | |
| Total Debt | $3.22B | $3.15B | $3.90B | $4.39B | $4.98B | $1.61B | $2.06B | $1.88B | $1.79B | $1.05B | $1.01B | $1.05B | |
| Common Stock | $112M | $121M | $123M | $126M | $126M | $112M | $111M | $111M | $110M | $110M | $112M | $112M | |
| Retained Earnings | $6.05B | $5.85B | $5.61B | $4.95B | $4.42B | $3.51B | $2.81B | $2.60B | $2.38B | $2.12B | $1.99B | $1.81B | |
| AOCI | $-222M | $-396M | $-277M | $-447M | $-163M | $-32M | $-200M | $-176M | $-47M | $-101M | $-46M | $25M | |
| Stockholders' Equity | $7.25B | $7.67B | $7.87B | $7.38B | $7.14B | $3.74B | $2.81B | $2.58B | $2.50B | $2.15B | $2.11B | $2.04B | |
| Liabilities + Equity | $12.17B | $12.39B | $13.56B | $14.13B | $15.00B | $7.96B | $6.54B | $5.98B | $6.09B | $4.28B | $4.17B | $4.13B | |
| Shares Outstanding | 112,281,000 | 120,646,000 | 0 | 126,300,000 | 126,241,000 | 112,090,000 | 111,140,000 | 110,361,000 | 110,361,000 | 109,617,000 | 112,481,000 | 112,481,000 |
현금 흐름
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $405M | $428M | $432M | $427M | $311M | $202M | $214M | $181M | $105M | $100M | $105M | $110M | |
| Stock-based Comp | $23M | $38M | $41M | $52M | $30M | $27M | $32M | $29M | $25M | $17M | $17M | $14M | |
| Deferred Tax | $-61M | $-102M | $-124M | $-106M | $-55M | $-35M | $-61M | $-51M | $29M | $-5M | $-10M | $-34M | |
| Amort. of Intangibles | $336M | $359M | $365M | $371M | $257M | $161M | $164M | $136M | $74M | $72M | $77M | $81M | |
| Restructuring | · | $18M | $27M | $14M | $-14M | $8M | $29M | $11M | $13M | $5M | $14M | $13M | |
| Other Non-cash | $-25M | $-6M | $-951M | $-262M | $126M | $-82M | $-48M | $-85M | $-163M | $4M | $-48M | $26M | |
| Operating Cash Flow | $583M | $628M | $91M | $680M | $1.41B | $892M | $363M | $311M | $288M | $351M | $287M | $282M | |
| CapEx | $74M | $87M | $81M | $86M | $86M | $64M | $76M | $93M | $39M | $32M | $28M | $27M | |
| Investing Cash Flow | $-17M | $776M | $1.31B | $-133M | $-4.11B | $-504M | $-488M | $-160M | $-1.27B | $-84M | $-101M | $-296M | |
| Stock Repurchased | $821M | $370M | $389M | $81M | $73M | $7M | $6M | $57M | $4M | $152M | $76M | $66M | |
| Net Stock Activity | $-821M | $-370M | $-389M | $-81M | $-73M | $-7M | $-6M | $-57M | $-4M | $-152M | $-76M | $-66M | |
| Dividends Paid | $33M | $34M | $35M | $35M | $32M | $31M | $31M | $31M | $31M | $31M | $32M | $32M | |
| Financing Cash Flow | $-858M | $-1.13B | $-947M | $-662M | $2.94B | $-203M | $-150M | $-179M | $782M | $-115M | $-107M | $31M | |
| Net Change in Cash | $-243M | $250M | $444M | $-149M | $217M | $211M | $26M | $-36M | $-174M | $138M | $63M | $2M | |
| Taxes Paid | $131M | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $509M | $542M | $10M | $594M | $1.31B | $815M | $287M | $218M | $249M | $319M | $257M | $253M | |
| Levered FCF | · | · | · | · | · | $775M | $226M | $156M | $226M | $282M | $224M | $218M |
수익성
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | 60.1% | · | 55.8% | 48.4% | 48.3% | 47.5% | 47.9% | 45.3% | 44.9% | |
| Operating Margin | 12.5% | 12.6% | 10.9% | 22.4% | 26.3% | 25.9% | 12.6% | 11.7% | 13.5% | 13.4% | 12.7% | 9.4% | |
| Net Margin | 8.5% | 9.8% | 25.2% | 17.2% | 18.6% | 19.2% | 7.9% | 8.6% | 13.0% | 11.1% | 9.4% | 7.0% | |
| Pretax Margin | 9.4% | 11.5% | 6.7% | 19.7% | 25.3% | 24.0% | 8.2% | 9.3% | 13.2% | 11.5% | 10.8% | 7.6% | |
| EBITDA Margin | 26.7% | 28.1% | 26.6% | 35.3% | 33.4% | 32.4% | 20.0% | 18.2% | 18.2% | 18.1% | 17.6% | 14.6% | |
| ROA | 2.0% | 2.1% | 5.0% | 3.9% | 8.2% | 10.0% | 3.6% | 3.9% | 5.6% | 5.5% | 5.1% | 3.9% | |
| ROE | 3.3% | 3.5% | 8.9% | 7.9% | 13.4% | 20.9% | 8.2% | 9.2% | 12.6% | 11.0% | 10.2% | 7.8% | |
| ROIC | 3.0% | 2.9% | 2.5% | 5.0% | 8.1% | 14.7% | 7.1% | 6.7% | 3.8% | 7.8% | 8.0% | 6.5% |
유동성 및 지급능력
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.7 | 3.6 | 2.1 | 2.1 | 2.0 | 1.4 | 1.8 | 1.6 | 1.3 | 2.0 | 1.8 | 1.8 | |
| Quick Ratio | 1.3 | 2.7 | 1.5 | 0.7 | 1.4 | 0.9 | 1.2 | 1.0 | 0.8 | 1.3 | 1.2 | 1.1 | |
| Debt / Equity | 0.4 | 0.4 | 0.5 | 0.6 | 0.7 | 0.4 | 0.7 | 0.7 | 0.7 | 0.5 | 0.5 | 0.5 | |
| LT Debt / Equity | 0.4 | 0.4 | 0.4 | 0.5 | 0.7 | 0.4 | 0.7 | 0.7 | 0.7 | 0.5 | 0.5 | 0.5 | |
| Interest Coverage | · | · | · | · | · | 19.7 | 5.7 | 4.8 | 6.9 | 6.8 | 7.5 | 5.8 |
효율성
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | 0.2 | 0.2 | 0.4 | 0.5 | 0.5 | 0.5 | 0.4 | 0.5 | 0.5 | 0.6 | |
| Inventory Turnover | · | · | · | · | · | · | · | 4.2 | 2.4 | 2.6 | 2.8 | 2.9 | |
| Receivables Turnover | 4.1 | 4.4 | 4.4 | 5.0 | 4.7 | 4.0 | 4.2 | 4.7 | 4.6 | 5.0 | 5.0 | 4.8 |
주당
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $64.57 | $63.55 | $63.79 | $58.46 | $56.57 | $33.33 | $25.44 | $23.37 | $22.68 | $19.22 | $18.84 | $18.16 | |
| Revenue / Share | $24.50 | $22.43 | $22.04 | $26.20 | $43.43 | $33.75 | $25.86 | $24.91 | $20.36 | $19.18 | $19.97 | $19.67 | |
| Cash Flow / Share | $5.00 | $5.12 | $0.73 | $5.38 | $12.09 | $7.96 | $3.26 | $2.79 | $2.60 | $3.18 | $2.53 | $2.48 | |
| Cash / Share | $8.19 | $9.64 | $7.40 | $3.60 | $4.90 | $3.59 | $1.73 | $1.47 | $1.83 | $3.21 | $2.12 | $1.55 | |
| Dividend / Share | $0.28 | $0.28 | $0.28 | $0.28 | · | $0.28 | $0.28 | $0.28 | $0.28 | $0.28 | $0.28 | $0.28 | |
| EPS (TTM) | $2.07 | $2.20 | $5.55 | $4.50 | $8.08 | $6.49 | $2.04 | $2.13 | $2.64 | $2.12 | $1.87 | $1.39 |
성장률
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 3.7% | 0.16% | -17.0% | -13.5% | 1.2% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -4.8% | -10.4% | -10.1% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -5.5% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -5.9% | -60.4% | 23.3% | -44.3% | 24.5% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -22.8% | -35.2% | -5.1% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -20.4% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -10.8% | -61.0% | 21.8% | -39.6% | 29.6% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -24.9% | -34.1% | -1.6% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -19.8% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 1.0% | · | · | · | · | · | · | · | · | · | · | · |
가치 평가 (TTM)
| 지표 | 추세 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.86B | $2.76B | $2.75B | $3.31B | $3.83B | $3.78B | $2.88B | $2.78B | $2.26B | $2.12B | $2.10B | $2.24B | |
| Net Income TTM | $241M | $270M | $693M | $569M | $943M | $728M | $228M | $238M | $293M | $234M | $212M | $158M | |
| Market Cap | $10.86B | $13.51B | $13.49B | $17.71B | $25.38B | $16.08B | $10.73B | $8.55B | $8.07B | $5.84B | $6.00B | $4.96B | |
| Enterprise Value | $13.16B | $15.50B | $15.79B | $21.65B | $29.74B | $17.29B | $12.61B | $10.26B | $9.66B | $6.53B | $6.78B | $5.83B | |
| P/E | 46.7 | 50.9 | 19.7 | 31.2 | 24.9 | 22.1 | 47.6 | 36.3 | 27.7 | 24.6 | 28.6 | 31.7 | |
| P/S | 3.8 | 4.9 | 4.9 | 5.3 | 6.6 | 4.3 | 3.7 | 3.1 | 3.6 | 2.8 | 2.9 | 2.2 | |
| P/B | 1.5 | 1.8 | 1.7 | 2.4 | 3.6 | 4.3 | 3.8 | 3.3 | 3.2 | 2.7 | 2.8 | 2.4 | |
| P / Cash Flow | 18.6 | 21.5 | 147.8 | 26.1 | 18.0 | 18.0 | 29.5 | 27.5 | 28.0 | 16.7 | 20.9 | 17.6 | |
| P / FCF | 21.3 | 24.9 | 1362.2 | 29.8 | 19.4 | 19.7 | 37.4 | 39.2 | 32.4 | 18.3 | 23.3 | 19.6 | |
| EV / EBITDA | 17.3 | 20.0 | 21.6 | 18.5 | 17.6 | 14.1 | 21.9 | 20.3 | 23.6 | 17.0 | 17.0 | 17.8 | |
| EV / FCF | 25.8 | 28.6 | 1594.1 | 36.4 | 22.7 | 21.2 | 43.9 | 47.1 | 38.7 | 20.5 | 26.3 | 23.1 | |
| EV / Revenue | 4.6 | 5.6 | 5.7 | 6.5 | 7.8 | 4.6 | 4.4 | 3.7 | 4.3 | 3.1 | 3.2 | 2.6 | |
| Dividend Yield | 0.30% | 0.26% | 0.26% | 0.20% | 0.13% | 0.19% | 0.29% | 0.36% | 0.38% | 0.53% | 0.53% | 0.64% | |
| Earnings Yield | 2.1% | 2.0% | 5.1% | 3.2% | 4.0% | 4.5% | 2.1% | 2.8% | 3.6% | 4.1% | 3.5% | 3.1% | |
| Payout Ratio | 13.6% | 12.7% | 5.0% | 6.2% | 3.4% | 4.3% | 13.7% | 13.0% | 10.5% | 13.2% | 14.9% | 20.0% | |
| Annual Payout | $33M | $34M | $35M | $35M | $32M | $31M | $31M | $31M | $31M | $31M | $32M | $32M |
손익계산서
| 지표 | 추세 | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $730M | $711M | $772M | $699M | $720M | $665M | $729M | $684M | $692M | $650M | $403M | $709M | $-120M | |
| Cost of Revenue | $313M | $323M | · | $324M | $328M | $289M | · | $299M | $306M | $295M | · | $307M | · | |
| Gross Profit | · | · | · | · | · | · | · | · | · | · | · | · | $436M | |
| R&D Expense | $49M | $58M | $58M | $51M | $53M | $54M | $49M | $49M | $48M | $50M | $45M | $57M | $40M | |
| SG&A Expense | $279M | $254M | $252M | $242M | $249M | $250M | $244M | $238M | $252M | $261M | $232M | $267M | $229M | |
| Operating Income | $89M | $76M | $112M | $82M | $91M | $72M | $119M | $98M | $86M | $44M | $-116M | $78M | $-290M | |
| Interest Expense | · | · | · | · | · | · | · | · | $25M | $24M | · | $26M | · | |
| Interest Income | $5M | $6M | $6M | $7M | $8M | $10M | $10M | $23M | $21M | $20M | $41M | $25M | $2M | |
| Other Non-op | $21M | $-26M | $-77M | $-4M | $13M | $-20M | $-26M | $-1M | $43M | $-10M | $-27M | $-7M | $-66M | |
| Pretax Income | $64M | $50M | $92M | $56M | $69M | $52M | $95M | $100M | $87M | $35M | $-143M | $72M | $-361M | |
| Income Tax | $10M | $9M | $-4M | $8M | $13M | $11M | $6M | $7M | $14M | $6M | $-55M | $13M | $-87M | |
| Net Income | $52M | $41M | $98M | $47M | $54M | $42M | $95M | $94M | $55M | $26M | $-89M | $36M | $-166M | |
| EPS (Basic) | $0.47 | $0.36 | $0.86 | $0.40 | $0.46 | $0.35 | $0.78 | $0.77 | $0.45 | $0.21 | $-0.63 | $0.28 | $-2.50 | |
| EPS (Diluted) | $0.47 | $0.36 | $0.86 | $0.40 | $0.46 | $0.35 | $0.77 | $0.77 | $0.45 | $0.21 | $-0.63 | $0.28 | $-2.48 | |
| Shares (Basic) | 111,584,000 | 111,852,000 | · | 115,411,000 | 117,512,000 | 120,137,000 | · | 122,810,000 | 123,354,000 | 123,428,000 | · | 125,215,000 | · | |
| Shares (Diluted) | 111,629,000 | 111,876,000 | · | 115,463,000 | 117,538,000 | 120,233,000 | · | 123,026,000 | 123,477,000 | 123,538,000 | · | 125,398,000 | · | |
| EBITDA | $89M | $181M | · | $82M | $91M | $170M | · | $98M | $86M | $152M | · | $78M | · |
대차대조표
| 지표 | 추세 | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.02B | $860M | $920M | $931M | $992M | $1.14B | $1.16B | $1.23B | $1.25B | $998M | $913M | $1.33B | $454M | |
| Short-term Investments | · | · | · | · | · | · | · | $0 | $706M | $697M | · | $739M | · | |
| Receivables | $709M | $691M | $745M | $680M | $661M | $617M | $632M | $602M | $597M | $589M | · | $627M | · | |
| Inventory | $379M | $388M | $379M | $380M | $388M | $381M | $368M | $405M | $401M | $414M | · | $437M | · | |
| Other Current Assets | $187M | $189M | $196M | $152M | $195M | $182M | $186M | $212M | $206M | $361M | · | $389M | · | |
| Current Assets | $2.30B | $2.13B | $2.24B | $2.14B | $2.24B | $2.32B | $2.35B | $2.45B | $3.16B | $3.06B | · | $3.52B | · | |
| PP&E (Net) | $456M | $466M | $479M | $497M | $499M | $487M | $482M | $518M | $503M | $504M | · | $491M | · | |
| PP&E (Gross) | · | · | $1.09B | · | · | · | $982M | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $614M | · | · | · | $500M | · | · | · | · | · | · | |
| Goodwill | $6.61B | $6.61B | $6.61B | $6.60B | $6.61B | $6.51B | $6.46B | $6.56B | $6.50B | $6.50B | $6.53B | $6.52B | $6.48B | |
| Intangibles | $2.22B | $2.31B | $2.35B | $2.43B | $2.51B | $2.57B | $2.64B | $2.76B | $2.83B | $2.92B | · | $3.20B | · | |
| Other Non-current Assets | $309M | $322M | $323M | $300M | $321M | $300M | $288M | $332M | $297M | $298M | · | $322M | · | |
| Total Assets | $12.05B | $12.00B | $12.17B | $12.14B | $12.36B | $12.36B | $12.39B | $12.77B | $13.42B | $13.43B | · | $14.22B | · | |
| Accounts Payable | $166M | $170M | $185M | $176M | $178M | $178M | $167M | $176M | $175M | $184M | · | $236M | · | |
| Accrued Liabilities | $538M | $493M | $557M | $463M | $493M | $470M | $485M | $510M | $504M | $479M | · | $652M | · | |
| Current Liabilities | $1.28B | $1.24B | $1.33B | $1.22B | $672M | $648M | $653M | $688M | $1.39B | $1.37B | · | $1.37B | · | |
| Capital Leases | $136M | $142M | $148M | $154M | $160M | $157M | $152M | $128M | $123M | $127M | · | $144M | · | |
| Other Non-current Liabilities | $771M | $801M | $807M | $755M | $760M | $750M | $771M | $846M | $879M | $920M | · | $954M | · | |
| Total Liabilities | $4.82B | $4.81B | $4.92B | $4.76B | $4.81B | $4.72B | $4.73B | $4.85B | $5.55B | $5.59B | · | $6.35B | · | |
| Long-term Debt | $3.21B | $3.21B | $3.22B | $3.21B | $3.21B | $3.17B | $3.15B | $3.19B | $3.87B | $3.88B | · | $4.36B | · | |
| Total Debt | $3.21B | $3.21B | · | $3.21B | $3.21B | $3.17B | · | $3.19B | $3.87B | $3.88B | · | · | · | |
| Common Stock | $112M | $112M | $112M | $114M | $116M | $119M | $121M | $122M | $123M | $123M | · | $124M | · | |
| Retained Earnings | $6.13B | $6.09B | $6.05B | $5.96B | $5.93B | $5.88B | $5.85B | $5.76B | $5.67B | $5.63B | · | $5.54B | · | |
| AOCI | $-257M | $-254M | $-222M | $-180M | $-157M | $-316M | $-396M | $-232M | $-342M | $-325M | $-277M | $-305M | $-447M | |
| Stockholders' Equity | $7.23B | $7.18B | $7.25B | $7.38B | $7.56B | $7.64B | $7.67B | $7.92B | $7.87B | $7.85B | $7.87B | $7.87B | $7.38B | |
| Liabilities + Equity | $12.05B | $12.00B | $12.17B | $12.14B | $12.36B | $12.36B | $12.39B | $12.77B | $13.42B | $13.43B | · | $14.22B | · | |
| Shares Outstanding | 111,584,000 | 111,629,000 | 112,281,000 | 114,030,000 | 116,331,000 | 119,409,000 | 120,646,000 | 122,091,000 | 123,368,000 | 123,492,000 | 0 | 124,347,000 | 0 |
현금 흐름
| 지표 | 추세 | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $102M | $105M | $103M | $102M | $103M | $97M | $105M | $108M | $106M | $108M | $106M | · | $104M | |
| Stock-based Comp | $11M | $9M | $-4M | $9M | $10M | $8M | $5M | $11M | $12M | $12M | $7M | · | $12M | |
| Amort. of Intangibles | $85M | $85M | $84M | $84M | $85M | $83M | $88M | $90M | $91M | $91M | $85M | $93M | $163M | |
| Other Non-cash | · | $-39M | · | · | · | $-19M | · | · | · | $2M | · | · | · | |
| Operating Cash Flow | $192M | $115M | $182M | $138M | $134M | $128M | $174M | $148M | $243M | $148M | $197M | · | $139M | |
| CapEx | $11M | $20M | $20M | $19M | $19M | $16M | $24M | $22M | $19M | $18M | $24M | · | $26M | |
| Investing Cash Flow | $-4M | $-78M | $-20M | $19M | $-9M | $-6M | $-17M | $690M | $-1.76B | $-18M | $-415M | · | $-26M | |
| Stock Repurchased | $16M | $86M | $168M | $205M | $294M | $154M | $185M | $154M | $-31M | $11M | $5M | · | $25M | |
| Net Stock Activity | · | $-86M | · | · | · | $-154M | · | · | · | $-11M | · | · | · | |
| Dividends Paid | $8M | $8M | $8M | $8M | $8M | $8M | $9M | $9M | $8M | $9M | $9M | · | $9M | |
| Financing Cash Flow | $-23M | $-89M | $-176M | $-215M | $-302M | $-164M | $-193M | $-874M | $52M | $-35M | $-20M | · | $-77M | |
| Net Change in Cash | $163M | $-60M | $-12M | $-60M | $-146M | $-26M | $-66M | $-19M | $-1.46B | $85M | $-224M | · | $54M | |
| Free Cash Flow | · | $95M | · | · | · | $112M | · | · | · | $130M | · | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $109M | · | · | · |
수익성
| 지표 | 추세 | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 12.2% | 10.7% | · | 11.7% | 12.6% | 10.9% | · | 14.3% | 12.4% | 6.8% | · | 11.0% | · | |
| Net Margin | 7.1% | 5.7% | · | 6.7% | 7.5% | 6.3% | · | 13.8% | 8.0% | 4.0% | · | 5.0% | · | |
| Pretax Margin | 8.7% | 7.0% | · | 8.0% | 9.5% | 7.9% | · | 14.7% | 12.5% | 5.3% | · | 10.1% | · | |
| EBITDA Margin | 12.2% | 25.4% | · | 11.7% | 12.6% | 25.5% | · | 14.3% | 12.4% | 23.4% | · | 11.0% | · | |
| ROA | 0.42% | 0.33% | · | 0.37% | 0.42% | 0.33% | · | 0.72% | 0.40% | 0.19% | · | · | · | |
| ROE | 0.70% | 0.55% | · | 0.61% | 0.70% | 0.55% | · | 1.2% | 0.70% | 0.33% | · | · | · | |
| ROIC | 0.72% | 0.60% | · | 0.66% | 0.68% | 0.53% | · | 0.82% | 0.61% | 0.31% | · | · | · |
유동성 및 지급능력
| 지표 | 추세 | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.8 | 1.7 | · | 1.8 | 3.3 | 3.6 | · | 3.6 | 2.3 | 2.2 | · | · | · | |
| Quick Ratio | 1.4 | 1.3 | · | 1.3 | 2.5 | 2.7 | · | 2.7 | 1.8 | 1.7 | · | · | · | |
| Debt / Equity | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.5 | 0.5 | · | · | · | |
| LT Debt / Equity | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | 0.4 | 0.4 | 0.4 | · | · | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | 3.5 | 1.8 | · | 3.0 | · |
효율성
| 지표 | 추세 | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | · | · | |
| Inventory Turnover | 0.8 | 0.8 | · | 0.8 | 0.8 | 0.7 | · | 0.7 | 0.7 | 0.7 | · | · | · | |
| Receivables Turnover | 1.1 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | 1.1 | 1.1 | 1.1 | · | · | · |
주당
| 지표 | 추세 | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $64.78 | $64.34 | · | $64.68 | $64.95 | $63.96 | · | $64.88 | $63.80 | $63.54 | · | · | · | |
| Revenue / Share | $6.54 | $6.36 | · | $6.05 | $6.13 | $5.53 | · | $5.56 | $5.60 | $5.26 | · | $5.65 | · | |
| Cash Flow / Share | · | $1.03 | · | · | · | $1.07 | · | · | · | $1.19 | · | · | · | |
| Cash / Share | $9.17 | $7.71 | · | $8.17 | $8.53 | $9.53 | · | $10.07 | $10.12 | $8.08 | · | · | · | |
| Dividend / Share | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | $0.07 | |
| Dividend Paid / Share | · | · | · | · | · | · | · | $0.07 | $0.07 | $0.07 | · | $0.07 | · | |
| EPS (TTM) | $2.09 | $2.08 | · | $1.98 | $2.35 | $2.34 | · | $0.80 | $0.11 | $-0.06 | · | · | $4.50 |
가치 평가 (TTM)
| 지표 | 추세 | Q2 2027 | Q1 2027 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.91B | $2.90B | · | $2.81B | $2.80B | $2.77B | · | $2.43B | $2.42B | $2.43B | · | · | $3.31B | |
| Net Income TTM | · | · | · | $237M | $285M | $287M | · | $87M | $2M | $-18M | · | · | $569M | |
| Market Cap | $12.69B | $9.93B | · | $9.59B | $11.38B | $12.61B | · | $15.39B | $12.94B | $12.97B | · | · | · | |
| Enterprise Value | $14.88B | $12.28B | · | $11.87B | $13.60B | $14.64B | · | $17.35B | $14.86B | $15.15B | · | · | · | |
| P/E | 54.4 | 42.8 | · | 42.5 | 41.6 | 45.1 | · | 157.6 | 953.3 | -1750.0 | · | · | 31.2 | |
| P/S | 4.4 | · | · | 3.4 | 4.1 | 4.6 | · | 6.3 | 5.4 | 5.3 | · | · | · | |
| P/B | 1.8 | 1.4 | · | 1.3 | 1.5 | 1.7 | · | 1.9 | 1.6 | 1.7 | · | · | · | |
| P / Cash Flow | · | 86.2 | · | · | · | 98.4 | · | · | · | 87.9 | · | · | · | |
| EV / Revenue | 5.1 | · | · | 4.2 | 4.9 | 5.3 | · | 7.1 | 6.1 | 6.2 | · | · | · | |
| Dividend Yield | 0.25% | · | · | 0.35% | 0.30% | 0.27% | · | 0.22% | 0.27% | · | · | · | · | |
| Earnings Yield | 1.8% | 2.3% | · | 2.4% | 2.4% | 2.2% | · | 0.63% | 0.10% | -0.06% | · | · | 3.2% | |
| Payout Ratio | · | 19.2% | · | · | · | 20.0% | · | · | · | 33.2% | · | · | · | |
| Annual Payout | $32M | $32M | · | $33M | $34M | $34M | · | $34M | $34M | · | · | · | $35M |
최신 기간은 왼쪽에 · null 값은 ·로 표시
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
| 지표 | 2025-12-28 | 2024-12-29 | 2023-12-31 | 2023-01-01 | 2022-01-02 |
|---|---|---|---|---|---|
| 매출 | $2.86B | $2.76B | $2.75B | $3.31B | $3.83B |
| 매출 총이익률 % | · | · | · | 60.1% | · |
| 영업이익률 % | 12.5% | 12.6% | 10.9% | 22.4% | 26.3% |
| 순이익 | $241M | $270M | $693M | $569M | $943M |
| 희석 EPS | $2.07 | $2.20 | $5.55 | $4.50 | $8.08 |
| 지표 | 2025-12-28 | 2024-12-29 | 2023-12-31 | 2023-01-01 | 2022-01-02 |
|---|---|---|---|---|---|
| 부채 / 자기자본 비율 | 0.4 | 0.4 | 0.5 | 0.6 | 0.7 |
| 유동비율 | 1.7 | 3.6 | 2.1 | 2.1 | 2.0 |
| 당좌 비율 | 1.3 | 2.7 | 1.5 | 0.7 | 1.4 |
| 지표 | 2025-12-28 | 2024-12-29 | 2023-12-31 | 2023-01-01 | 2022-01-02 |
|---|---|---|---|---|---|
| 잉여현금흐름 | $509M | $542M | $10M | $594M | $1.31B |
기관 투자자 (13F) 577개의 제출자 · $11.1B 전체 · 기준일 2026년 9월 30일
분기별 SEC 양식 13F에서 이 주식을 보유하고 있다고 보고하는 기관. 롱 포지션만 해당하며, 단일 제출자는 별도의 옵션 레그에 대해 두 번 나타날 수 있습니다. 대규모 상쇄 풋/콜 포지션은 일반적으로 방향성에 대한 확신보다는 시장 조성 또는 헤지된 재고를 반영합니다.
| 신규 포지션 | 청산 포지션 | 증가함 | 감소 | 순주식 변동 |
|---|---|---|---|---|
| 101 (+19 이전 분기 대비) | 53 (-14 이전 분기 대비) | 195 (+16 이전 분기 대비) | 163 (+4 이전 분기 대비) | -8.8M |
Q1 2026 대비 비교. SEC 양식 13F 제출은 분기 말로부터 45일 이내에 마감되며, 지연 제출자를 위한 짧은 유예 기간이 추가됩니다. 해당 기간 내에 있는 분기는 가장 최근에 완전히 보고된 쌍을 선호하여 건너뜁니다.
| 기관 | 가치 | 주식 | % 추적된 13F 중 | 유형 |
|---|---|---|---|---|
| VANGUARD GROUP INC | $1,273,316,785 | 13,160,897 | 11.42% | 주식 |
| EdgePoint Investment Group Inc. | $950,658,734 | 8,544,479 | 8.53% | 주식 |
| BlackRock, Inc. | $852,070,090 | 7,658,369 | 7.64% | 주식 |
| VANGUARD CAPITAL MANAGEMENT LLC | $812,306,256 | 7,300,973 | 7.29% | 주식 |
| JANUS HENDERSON GROUP PLC | $731,386,229 | 8,348,127 | 6.56% | 주식 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $530,760,044 | 4,770,448 | 4.76% | 주식 |
| STATE STREET CORP | $483,173,141 | 4,342,739 | 4.33% | 주식 |
| VICTORY CAPITAL MANAGEMENT INC | $384,362,134 | 3,454,630 | 3.45% | 주식 |
| DIMENSIONAL FUND ADVISORS LP | $381,477,581 | 3,428,692 | 3.42% | 주식 |
| GEODE CAPITAL MANAGEMENT, LLC | $328,197,297 | 2,955,227 | 2.94% | 주식 |
| MORGAN STANLEY | $286,475,399 | 2,574,826 | 2.57% | 주식 |
| Invesco Ltd. | $269,802,164 | 2,424,970 | 2.42% | 주식 |
| Allspring Global Investments Holdings, LLC | $251,393,303 | 2,227,874 | 2.25% | 주식 |
| NEUBERGER BERMAN GROUP LLC | $208,728,363 | 1,876,041 | 1.87% | 주식 |
| UBS Group AG | $207,440,264 | 1,864,464 | 1.86% | 주식 |
| Pictet Asset Management Holding SA | $181,501,112 | 1,631,343 | 1.63% | 주식 |
| CITADEL ADVISORS LLC | $162,143,092 | 1,457,335 | 1.45% | 주식 |
| RGM Capital, LLC | $147,000,789 | 1,519,388 | 1.32% | 주식 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $120,784,746 | 1,085,608 | 1.08% | 주식 |
| VAUGHAN NELSON INVESTMENT MANAGEMENT, L.P. | $120,187,725 | 1,080,242 | 1.08% | 주식 |
| NORTHERN TRUST CORP | $105,092,080 | 944,563 | 0.94% | 주식 |
| GOLDMAN SACHS GROUP INC | $100,173,074 | 900,351 | 0.90% | 주식 |
| WELLINGTON MANAGEMENT GROUP LLP | $96,303,874 | 865,575 | 0.86% | 주식 |
| NORGES BANK | $96,183,046 | 864,489 | 0.86% | 주식 |
| PRIMECAP MANAGEMENT CO/CA/ | $94,921,470 | 853,150 | 0.85% | 주식 |
| BANK OF AMERICA CORP /DE/ | $87,116,298 | 782,997 | 0.78% | 주식 |
| Bank of New York Mellon Corp | $78,765,533 | 707,941 | 0.71% | 주식 |
| VANGUARD FIDUCIARY TRUST CO | $69,620,945 | 625,750 | 0.62% | 주식 |
| JANE STREET GROUP, LLC | $64,087,317 | 576,014 | 0.57% | 주식 |
| JPMORGAN CHASE & CO | $54,177,057 | 481,955 | 0.49% | 주식 |
| FMR LLC | $51,807,384 | 465,642 | 0.46% | 주식 |
| SEI INVESTMENTS CO | $48,628,856 | 437,074 | 0.44% | 주식 |
| Quantinno Capital Management LP | $47,076,898 | 423,125 | 0.42% | 주식 |
| DEUTSCHE BANK AG\ | $45,437,583 | 408,391 | 0.41% | 주식 |
| FEDERATED HERMES, INC. | $43,043,267 | 386,871 | 0.39% | 주식 |
| Diamond Hill Capital Management, LLC (Investment Advisor) | $42,868,033 | 385,296 | 0.38% | 주식 |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $41,752,209 | 476,569 | 0.37% | 주식 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $41,048,042 | 368,938 | 0.37% | 주식 |
| Freestone Grove Partners LP | $36,716,134 | 330,003 | 0.33% | 주식 |
| Legal & General Group Plc | $31,388,230 | 282,116 | 0.28% | 주식 |
| CIBC Bancorp USA Inc. | $29,112,955 | 261,625 | 0.26% | 주식 |
| Nuveen, LLC | $27,202,014 | 244,491 | 0.24% | 주식 |
| California Public Employees Retirement System | $27,021,271 | 242,866 | 0.24% | 주식 |
| BNP PARIBAS FINANCIAL MARKETS | $25,920,242 | 232,970 | 0.23% | 주식 |
| WEDGE CAPITAL MANAGEMENT L L P/NC | $25,784,587 | 294,311 | 0.23% | 주식 |
| Vanguard Global Advisers, LLC | $25,557,201 | 229,707 | 0.23% | 주식 |
| Swiss National Bank | $24,955,618 | 224,300 | 0.22% | 주식 |
| CIBC Private Wealth Group LLC | $23,946,556 | 273,207 | 0.21% | 주식 |
| Artisan Partners Limited Partnership | $22,320,536 | 200,616 | 0.20% | 주식 |
| Meridiem Capital Partners LP | $21,483,638 | 193,094 | 0.19% | 주식 |
행동주의자 및 5% 이상 소유자 2 보유
SEC 서류 13D를 제출한 투자자 — 발행인에 영향을 미치려는 의도로 5% 이상의 실질 소유권(행동주의 지분, 이사회 캠페인, M&A). 각 행은 해당 제출자의 포지션에 대한 가장 최근에 알려진 상태를 보여줍니다.
| 제출자 | 제출됨 | 지분 | 상태 | 목적 | 제출 |
|---|---|---|---|---|---|
| PERKINELMER, INC. | 2011년 9월 16일 | · | 최초 제출 | M&A / 매각 | SEC |
| 미공개 보고자 | 2001년 7월 23일 | · | 최초 제출 | M&A / 매각 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
회사 내부자 46 명의 내부자 · 27 임원 · 20 이사
| 내부자 | 역할 | 마지막 활동 | 보유 주식 수 | 매수 12개월 | 매도 12개월 | 순매수/매도 12개월 |
|---|---|---|---|---|---|---|
| Robert F Friel | Chairman and CEO | 2019년 2월 13일 F | 570,662 | 0 | 0 | $0 |
| Maxwell Krakowiak | Senior Vice President and Chief Financial Officer | 2026년 9월 21일 S | 14,781 | 0 | 1 | $-235,728 |
| James M Mock | Senior Vice President and Chief Financial Officer | 2022년 6월 24일 S | 27,577 | 0 | 0 | $0 |
| Frank Anders Wilson | Senior Vice President and Chief Financial Officer | 2018년 3월 5일 M | 61,925 | 0 | 0 | $0 |
| Jeffrey D Capello | SVP & CFO | 2008년 1월 29일 A | 91,428 | 0 | 0 | $0 |
| John Patrick Murphy | Chief Operating Officer | 2005년 8월 1일 M | 68,589 | 0 | 0 | $0 |
| Anita Gonzales | VP and CAO | 2026년 10월 1일 S | 7,117 | 0 | 3 | $-29,790 |
| Tajinder Vohra | Senior Vice President, Global Operations | 2026년 9월 16일 S | 6,635 | 0 | 2 | $-1,634,152 |
| Joel S Goldberg | Senior Vice President, Administration, General Counsel and Secretary | 2026년 8월 14일 G | 91,494 | 0 | 4 | $-1,274,357 |
| Miriame Victor | Senior Vice President, Chief Commercial Officer | 2026년 2월 24일 M | 18,122 | 0 | 1 | $-180,856 |
| Daniel R Tereau | Senior Vice President, Strategy and Business Development | 2024년 2월 5일 A | 13,246 | 0 | 0 | $0 |
| Andrew Okun | Vice President, Chief Accounting Officer and Treasurer | 2023년 4월 13일 M | 4,356 | 0 | 0 | $0 |
| Deborah A. Butters | Senior Vice President, Chief Human Resources Officer | 2020년 2월 7일 F | 12,383 | 0 | 0 | $0 |
| James Corbett | Executive Vice President and President, Discovery & Analytical Solutions | 2019년 4월 30일 F | 40,531 | 0 | 0 | $0 |
| Jonathan P. Divincenzo | Senior Vice President and President, Environmental Health | 2016년 2월 9일 A | 23,158 | 0 | 0 | $0 |
| John R Letcher | Senior Vice President, Human Resources | 2015년 6월 5일 D | 26,894 | 0 | 0 | $0 |
| Maurice H. Tenney | Senior Vice President, Global Operations and Customer Logistics | 2014년 11월 7일 D | 12,241 | 0 | 0 | $0 |
| Daniel R Marshak | SVP & CSO | 2014년 9월 26일 D | 67,743 | 0 | 0 | $0 |
| Kevin E Hrusovsky | Senior Vice President, President Life Sciences and Technology | 2013년 5월 31일 D | 0 | 0 | 0 | $0 |
| John A Roush | Senior Vice President | 2010년 2월 9일 A | 120,407 | 0 | 0 | $0 |
| Richard F Walsh | SVP & CAO | 2010년 1월 26일 D | 183,491 | 0 | 0 | $0 |
| Gregory L Summe | Exe. Chairman of the Board | 2009년 2월 27일 S | 231,724 | 0 | 0 | $0 |
| Michael Louis Battles | VP & Chief Accounting Officer | 2009년 2월 3일 A | 33,750 | 0 | 0 | $0 |
| Katherine A Ohara | SVP, Gen. Counsel, & Secretary | 2008년 1월 29일 A | 65,886 | 0 | 0 | $0 |
| Peter B Coggins | Sr. Vice President | 2005년 10월 28일 M | 87,070 | 0 | 0 | $0 |
| Robert A Barrett | Sr. Vice President | 2004년 3월 3일 M | 2,333 | 0 | 0 | $0 |
| Terrance L Carlson | Sr. VP & General Counsel | 2004년 1월 27일 J | 2,759 | 0 | 0 | $0 |
| Alexis P. Michas | 이사 | 2026년 8월 25일 G | 6,985 | 0 | 0 | $0 |
| Michelle Mcmurry-Heath | 이사 | 2026년 5월 7일 A | 6,513 | 0 | 1 | $-58,356 |
| Michael A Klobuchar | 이사 | 2026년 5월 7일 A | 7,368 | 0 | 0 | $0 |
| Pascale Witz | 이사 | 2026년 5월 7일 A | 15,985 | 0 | 0 | $0 |
| Samuel R. Chapin | 이사 | 2026년 5월 7일 A | 22,676 | 0 | 0 | $0 |
| Michel Vounatsos | 이사 | 2026년 5월 7일 A | 13,977 | 0 | 0 | $0 |
| Frank Witney | 이사 | 2026년 5월 7일 A | 23,354 | 0 | 0 | $0 |
| Sophie V. Vandebroek | 이사 | 2026년 5월 7일 A | 7,368 | 0 | 0 | $0 |
| Peter Barrett | 이사 | 2026년 5월 7일 A | 28,293 | 0 | 0 | $0 |
| Sylvie Gregoire | 이사 | 2023년 5월 15일 A | 20,482 | 0 | 0 | $0 |
| SULLIVAN PATRICK J | 이사 | 2019년 4월 30일 A | 30,580 | 0 | 0 | $0 |
| Nicholas A Lopardo | 이사 | 2019년 2월 5일 S | 39,635 | 0 | 0 | $0 |
| Vicki L Sato | 이사 | 2017년 2월 9일 M | 29,970 | 0 | 0 | $0 |
| Kenton J Sicchitano | 이사 | 2016년 8월 24일 M | 27,971 | 0 | 0 | $0 |
| MULLEN JAMES C | 이사 | 2014년 11월 14일 M | 45,551 | 0 | 0 | $0 |
| Gabriel Schmergel | 이사 | 2012년 2월 16일 M | 48,012 | 0 | 0 | $0 |
| Robert G Tod | 이사 | 2012년 2월 14일 M | 42,824 | 0 | 0 | $0 |
| Tamara J Erickson | 이사 | 2007년 2월 14일 S | 15,352 | 0 | 0 | $0 |
| Prahlad R. Singh | · | 2026년 8월 13일 G | 59,650 | 0 | 5 | $-2,557,859 |
SEC 양식 3/4/5 제출 서류 기준 내부자; 순매수/매도는 공개 시장 거래만 해당
ETF 보유 현황 97 ETF 보유
가중치는 직접적인 주식 보유(N-PORT)만 반영합니다. 레버리지 또는 파생 상품 기반 펀드는 표시되지 않은 추가 스왑 노출을 보유할 수 있습니다.
| 펀드 | 비중 | 단위 | 기준일 | 출처 |
|---|---|---|---|---|
| RSPH · Invesco Exchange-Traded Fund Trust | 1.99% | 116,224 SH | 2026년 10월 2일 | 일간 |
| HTEC · EXCHANGE TRADED CONCEPTS TRUST | 1.13% | 6,936 NS | 2026년 7월 31일 | N-PORT |
| ALTL · Pacer Funds Trust | 0.98% | 8,002 NS | 2026년 7월 31일 | N-PORT |
| SPHB · Invesco Exchange-Traded Fund Trust … | 0.83% | 53,854 SH | 2026년 10월 2일 | 일간 |
| HIBL · Direxion Shares ETF Trust | 0.66% | 4,421 NS | 2026년 7월 31일 | N-PORT |
| PDP · Invesco Exchange-Traded Fund Trust | 0.62% | 61,941 SH | 2026년 10월 2일 | 일간 |
| IQSM · New York Life Investments ETF Trust | 0.50% | 14,749 NS | 2026년 7월 31일 | N-PORT |
| DFSV · Dimensional ETF Trust | 0.43% | 313,113 NS | 2026년 7월 31일 | N-PORT |
| FXH · First Trust Exchange-Traded AlphaDE… | 0.43% | 39,813 NS | 2026년 7월 31일 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0.36% | 14,789 NS | 2026년 7월 31일 | N-PORT |
| DFAT · Dimensional ETF Trust | 0.35% | 444,437 NS | 2026년 7월 31일 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 0.33% | 36,968 SH | 2026년 10월 2일 | 일간 |
| BKMC · BNY Mellon ETF Trust | 0.32% | 18,499 NS | 2026년 7월 31일 | N-PORT |
| ESML · iShares Trust | 0.29% | 66,388 SH | 2026년 9월 11일 | 일간 |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0.27% | 49,018 NS | 2026년 7월 31일 | N-PORT |
| VBR · VANGUARD INDEX FUNDS | 0.26% | 1,624,934 SH | 2026년 8월 19일 | 일간 |
| RSP · Invesco Exchange-Traded Fund Trust | 0.25% | 1,577,173 SH | 2026년 10월 2일 | 일간 |
| IYH · iShares Trust | 0.22% | 65,502 SH | 2026년 9월 11일 | 일간 |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.21% | 8,343 NS | 2026년 7월 31일 | N-PORT |
| SMMD · iShares Trust | 0.19% | 59,552 SH | 2026년 9월 11일 | 일간 |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0.18% | 5,732,000 | 2026년 10월 2일 | 일간 |
| FHLC · FIDELITY COVINGTON TRUST | 0.18% | 53,129 NS | 2026년 7월 31일 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.18% | 335,880 SH | 2026년 8월 19일 | 일간 |
| DFAS · Dimensional ETF Trust | 0.18% | 241,849 NS | 2026년 7월 31일 | N-PORT |
| ISCG · iShares Trust | 0.18% | 13,989 SH | 2026년 9월 11일 | 일간 |
| IXJ · iShares Trust | 0.17% | 58,518 SH | 2026년 9월 11일 | 일간 |
| REVS · Columbia ETF Trust I | 0.17% | 4,910 NS | 2026년 7월 31일 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0.15% | 2,559,509 SH | 2026년 8월 19일 | 일간 |
| CURE · Direxion Shares ETF Trust | 0.14% | 2,195 NS | 2026년 7월 31일 | N-PORT |
| IWS · iShares Trust | 0.13% | 167,213 SH | 2026년 9월 11일 | 일간 |
| WSML · iShares Trust | 0.13% | 7,071 SH | 2026년 9월 11일 | 일간 |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0.12% | 6,250 SH | 2026년 10월 2일 | 일간 |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0.12% | 8,519 NS | 2026년 7월 31일 | N-PORT |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0.11% | 4,047,000 | 2026년 10월 2일 | 일간 |
| RECS · Columbia ETF Trust I | 0.11% | 55,761 NS | 2026년 7월 31일 | N-PORT |
| PEXL · Pacer Funds Trust | 0.10% | 460 NS | 2026년 7월 31일 | N-PORT |
| IWR · iShares Trust | 0.10% | 456,822 SH | 2026년 9월 11일 | 일간 |
| XT · iShares Trust | 0.08% | 25,072 SH | 2026년 9월 11일 | 일간 |
| XOEF · iShares Trust | 0.08% | 142 SH | 2026년 9월 11일 | 일간 |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0.08% | 115,000 | 2026년 10월 2일 | 일간 |
| FNX · First Trust Exchange-Traded AlphaDE… | 0.08% | 9,258 NS | 2026년 7월 31일 | N-PORT |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0.06% | 4,182 SH | 2026년 10월 2일 | 일간 |
| DFAC · Dimensional ETF Trust | 0.06% | 238,422 NS | 2026년 7월 31일 | N-PORT |
| DXUV · Dimensional ETF Trust | 0.05% | 2,685 NS | 2026년 7월 31일 | N-PORT |
| DFSU · Dimensional ETF Trust | 0.05% | 10,422 NS | 2026년 7월 31일 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0.05% | 33,073 SH | 2026년 10월 2일 | 일간 |
| DFUV · Dimensional ETF Trust | 0.05% | 65,386 NS | 2026년 7월 31일 | N-PORT |
| IVE · iShares Trust | 0.05% | 185,121 SH | 2026년 9월 11일 | 일간 |
| IUSV · iShares Trust | 0.04% | 98,188 SH | 2026년 9월 11일 | 일간 |
| VOOV · VANGUARD ADMIRAL FUNDS | 0.04% | 25,806 SH | 2026년 8월 19일 | 일간 |
| DSI · iShares Trust | 0.04% | 17,178 SH | 2026년 9월 11일 | 일간 |
| DCOR · Dimensional ETF Trust | 0.04% | 11,339 NS | 2026년 7월 31일 | N-PORT |
| CHRI · Global X Funds | 0.04% | 27 NS | 2026년 7월 31일 | N-PORT |
| IWD · iShares Trust | 0.04% | 247,738 SH | 2026년 9월 11일 | 일간 |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.03% | 67,429 SH | 2026년 8월 19일 | 일간 |
| QVML · Invesco Exchange-Traded Fund Trust … | 0.03% | 3,368 SH | 2026년 10월 2일 | 일간 |
| TOPC · iShares Trust | 0.03% | 72 SH | 2026년 9월 11일 | 일간 |
| PBP · Invesco Exchange-Traded Fund Trust | 0.03% | 660 SH | 2026년 10월 2일 | 일간 |
| TILT · FlexShares Trust | 0.02% | 4,536 NS | 2026년 7월 31일 | N-PORT |
| XVV · iShares Trust | 0.02% | 1,280 SH | 2026년 9월 11일 | 일간 |
| DFAU · Dimensional ETF Trust | 0.02% | 24,920 NS | 2026년 7월 31일 | N-PORT |
| PHDG · Invesco Actively Managed Exchange-T… | 0.02% | 89 SH | 2026년 10월 2일 | 일간 |
| XYLG · Global X Funds | 0.02% | 120 NS | 2026년 7월 31일 | N-PORT |
| IVV · iShares Trust | 0.02% | 1,406,050 SH | 2026년 9월 11일 | 일간 |
| XYLD · Global X Funds | 0.02% | 5,804 NS | 2026년 7월 31일 | N-PORT |
| VOO · VANGUARD INDEX FUNDS | 0.02% | 2,897,314 SH | 2026년 8월 19일 | 일간 |
| VTI · VANGUARD INDEX FUNDS | 0.02% | 3,545,801 SH | 2026년 8월 19일 | 일간 |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.02% | 18,403 SH | 2026년 8월 19일 | 일간 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.02% | 9,418 SH | 2026년 8월 19일 | 일간 |
| ESGV · VANGUARD WORLD FUND | 0.02% | 25,220 SH | 2026년 8월 19일 | 일간 |
| IYY · iShares Trust | 0.02% | 4,913 SH | 2026년 9월 11일 | 일간 |
| PTLC · Pacer Funds Trust | 0.02% | 5,733 NS | 2026년 7월 31일 | N-PORT |
| IWB · iShares Trust | 0.02% | 77,050 SH | 2026년 9월 11일 | 일간 |
| XCLR · Global X Funds | 0.02% | 6 NS | 2026년 7월 31일 | N-PORT |
| ITOT · iShares Trust | 0.02% | 147,486 SH | 2026년 9월 11일 | 일간 |
| IWV · iShares Trust | 0.02% | 30,674 SH | 2026년 9월 11일 | 일간 |
| DFUS · Dimensional ETF Trust | 0.02% | 33,978 NS | 2026년 7월 31일 | N-PORT |
| XRMI · Global X Funds | 0.02% | 81 NS | 2026년 7월 31일 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0.02% | 421 NS | 2026년 7월 31일 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 0.02% | 11,711 SH | 2026년 10월 2일 | 일간 |
| QDPL · Pacer Funds Trust | 0.02% | 2,684 NS | 2026년 7월 31일 | N-PORT |
| XTR · Global X Funds | 0.02% | 7 NS | 2026년 7월 31일 | N-PORT |
| HCMT · Direxion Shares ETF Trust | 0.02% | 779 NS | 2026년 7월 31일 | N-PORT |
| SPXL · Direxion Shares ETF Trust | 0.01% | 8,723 NS | 2026년 7월 31일 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0.01% | 3,421 SH | 2026년 10월 2일 | 일간 |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.01% | 98,929 SH | 2026년 8월 19일 | 일간 |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | 2026년 7월 15일 | 일간 |
| BLV · VANGUARD BOND INDEX FUNDS | · | · | 2026년 7월 15일 | 일간 |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | 2026년 7월 15일 | 일간 |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 2026년 7월 15일 | 일간 |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | 2026년 7월 15일 | 일간 |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | 2026년 7월 15일 | 일간 |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | 2026년 7월 15일 | 일간 |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | 2026년 7월 30일 | 일간 |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 2026년 7월 14일 | 일간 |
| ISCB · iShares Trust | · | 5,032 SH | 2026년 9월 11일 | 일간 |
| ISCV · iShares Trust | · | 15,028 SH | 2026년 9월 11일 | 일간 |
RVTY 분석가 합의 강세 및 약세 애널리스트 의견, 12개월 목표 주가, 상승 여력
12개월 목표 주가
16 명의 애널리스트 · 2026-09-28평균 목표 $129.00 -14.9%
동종 기업 비교(GICS 하위 산업) 주요 지표 대 섹터 동종 기업
회계연도 기준, 각 회사의 마지막 회계연도 말 종가 기준 가격입니다.
| 티커 | 시가총액 | P/E | 매출 YoY | 순이익률 | ROE | 매출 총이익률 |
|---|---|---|---|---|---|---|
| RVTY | $10.86B | 46.7 | 3.7% | 8.5% | 3.3% | · |
| WAT | $22.62B | 35.3 | 7.0% | 20.3% | 27.2% | · |
| IQV | $38.23B | 28.8 | 5.9% | 8.3% | 21.6% | · |
| ILMN | $20.65B | 24.8 | -0.66% | 19.6% | 34.1% | 66.1% |
| MTD | $28.38B | 33.2 | 4.0% | 21.6% | -615.5% | 59.4% |
| WST | $19.81B | 40.5 | 6.2% | 16.1% | 16.2% | 35.9% |
| MEDP | $15.93B | 36.8 | 20.0% | 17.8% | 142.9% | · |
| TEM | · | -41.9 | 83.4% | -19.3% | -61.2% | · |
| CRL | $10.02B | -70.0 | -0.85% | -3.6% | -4.4% | · |
| TEM | · | -41.9 | 83.4% | -19.3% | -61.2% | · |
| TXG | $2.08B | -46.6 | 5.2% | -6.8% | -5.5% | 69.0% |
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
중요한 지표를 선택하세요. 상단의 전체 기본 정보에서 원하는 행 옆의 +를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.